The Psychopharmacologic Drugs Advisory Committee will discuss safety and efficacy issues for use of AstraZeneca's Seroquel for adolescent schizophrenia and childhood bipolar mania. They will also consider Pfizer's Geodon for "acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features in children and adolescents" and Eli Lilly's Zyprexa for those same episodes, as well as schizophrenia in adolescents. The committee is expected to vote on the effectiveness and safety of each application of each drug.
For location and scheduling information, or to register for public comment, visit the meeting's site.